Germany · Delayed Price · Currency is EUR Protalix BioTherapeutics Company Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases.
The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey.
The company is headquartered in Hackensack. New Jersey.
| Country | United States |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 213 |
| CEO | Dror Bashan |
Contact Details
Address: 2 University Plaza Hackensack, Delaware 07601 United States | |
| Phone | 201 696 9345 |
| Website | protalix.com |
Stock Details
| Ticker Symbol | PBDA |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dror Bashan | Chief Executive Officer |
| Gilad Mamlok | Chief Financial Officer |
| Yaron Naos | Chief Operating Officer |